SURGICAL PATHOLOGY CONSULTATION

SPECIMEN:
1. Right lateral base
2. Right medial base
3. Right lateral mid
4. Right medial mid
5. Right lateral apex
6. Left lateral base
7. Left medial base
8. Left lateral mid
9. Left medial mid
10. Left lateral apex

CLINICAL DATA: Elevated PSA (9.0)

FINAL DIAGNOSIS (Microscopic):
1. Prostate, right lateral base, needle biopsy -
   1. Prostatic adenocarcinoma, Gleason pattern 4 + 4 (total score 8).
   2. Tumor involves 5 mm of a 1.4 cm core biopsy length.
   3. Angiolymphatic and perineural space involvement not detected in this biopsy.
2. Prostate, right medial base, needle biopsy -
   1. Prostatic adenocarcinoma, Gleason pattern 4 + 4 (total score 8).
   2. Tumor involves 1 mm of a 1.7 cm core biopsy length.
   3. Angiolymphatic and perineural space involvement not detected in this biopsy.
3. Prostate, right lateral mid, needle biopsy -
   a. Prostatic adenocarcinoma, Gleason pattern 4 + 4 (total score 8).
   b. Tumor involves 6 mm of a 1.3 cm core biopsy length.
   c. Angiolymphatic and perineural space involvement not detected in this biopsy.
4. Prostate, right medial mid, needle biopsy -
   a. Benign prostate parenchyma.
   b. Negative for malignancy.
5. Prostate, right lateral apex, needle biopsy -
   a. Prostatic adenocarcinoma, Gleason pattern 4 + 4 (total score 8).
   b. Tumor involves 1 mm of a 1.9 cm core biopsy length.
   c. Angiolymphatic and perineural space involvement not detected in this biopsy.
6. Prostate, left lateral base, needle biopsy -
   a. Benign prostate parenchyma with minimal chronic prostatitis and regional
gland atrophy with stromal fibrosis.
b. Negative for malignancy.

7. Prostate, left medial base, needle biopsy-
   a. Benign prostate parenchyma with minimal chronic prostatitis and regional gland atrophy with stromal fibrosis.
   b. Negative for malignancy.

8. Prostate, left lateral mid, needle biopsy-
   a. Benign prostate parenchyma with minimal chronic prostatitis and regional gland atrophy with stromal fibrosis.
   b. Negative for malignancy.

9. Prostate, left medial mid, needle biopsy-
   a. Benign prostate parenchyma with reactive glandular changes and focal stromal fibrosis.
   b. Negative for malignancy.

10. Prostate, left lateral apex, needle biopsy-
    a. Benign prostate parenchyma with regional gland atrophy and stromal fibrosis.
    b. Negative for malignancy.

MICROSCOPIC: Prostatic adenocarcinoma is identified in specimens #1, 2, 3, 5. The tumor is characterized by expansile, non-gland forming sheets and nests of neoplastic cells. These have pale foamy cytoplasm and some cytoplasmic vacuolation. Tumor cell nuclei are round to ovoid with single prominent nucleoli in a substantial minority of cells. Due to the high Gleason grade and somewhat unusual cytologic features, PSA immunostain was performed on one of the positive biopsies. The strongly positive PSA confirms that this is prostatic adenocarcinoma.

Other biopsy sites (including all left side sites) show benign prostate tissue.

Sign-out pathologist: David L. Slater, MD; direct phone number (559) 326-2826

(Sierra Pathology Lab, Inc., 305 Park Creek Drive, Clovis, CA 93611-4426; William C. Pitts, M.D., FCAP, Medical Director)
The third specimen container is labeled with the patient name PATHOLOGY and RLM. It contains a single pale tan core biopsy 1.3 cm; as 3A.

The fourth specimen container is labeled with patient name PATHOLOGY and RM. It contains two pale tan core biopsy fragments 0.4 and 1.4 cm; as 4A.

The fifth specimen container is labeled with the patient name PATHOLOGY and RLA. It contains a single pale tan core biopsy 1.9 cm; as 5A.

The sixth specimen container is labeled with the patient name PATHOLOGY and LLB. It contains a single pale tan core biopsy 1.6 cm; as 6A.

The seventh specimen container is labeled with patient name PATHOLOGY and LB. It contains a single pale tan core biopsy 2.2 cm; as 7A.

The eighth specimen container is labeled with the patient name PATHOLOGY and LLM. It contains a single pale tan core biopsy 1.1 cm; as 8A.

The ninth specimen container is labeled with the patient name PATHOLOGY and LM. It contains a single pale tan core biopsy 2.1 cm; as 9A.

The tenth specimen container is labeled with the patient name PATHOLOGY and LLA. It contains two pale tan core biopsy fragments 0.6 and 1.1 cm; as 10A. WCP/ag/cad (7/2/2013 6:59 PM)

(Specimen grossing/histology performed at Sierra Pathology Lab, Inc., 305 Park Creek Dr., Clovis, CA 93611, William C. Pitts, MD, FCAP, Lab Medical Director)

**IMMUNOHISTOCHEMICAL/ISH STAIN(S) PERFORMED:**

Source Material: Block 3A
Population: Tumor Cells

<table>
<thead>
<tr>
<th>Label</th>
<th>Description</th>
<th>Score</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA</td>
<td>PSA - Prostate specific antigen antibody stain</td>
<td>Positive</td>
<td></td>
</tr>
</tbody>
</table>

Source Material: Block 7A
Population: Tumor Cells

<table>
<thead>
<tr>
<th>Label</th>
<th>Description</th>
<th>Score</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>HMW-CK</td>
<td>HMW-CK - Cytokeratin HMW-34BE12 prostate antibody stain</td>
<td>Focally positive</td>
<td>present but incomplete myoepithelial cells</td>
</tr>
</tbody>
</table>

Appropriate positive and negative controls were used for each immunohistochemical stain (IHC test) or in-situ hybridization (ISH). This test was developed and its performance characteristics determined by Sierra Pathology Laboratory, Inc. It has not been cleared or approved by the U. S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) as qualified to perform high complexity laboratory testing.

Final Diagnosis performed by David L. Slater MD, FCAP. Electronically signed 7/18/2013 11:54 AM